DBVT DBV Technologies S.A. - American Depositary Shares
NASDAQ · Biotechnology · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Jul 16, 2026
$10,55
· % dari rentang 52 mgg
· di atas terendah
· ke tinggi
$10,47rendah 52m
$26,19tinggi 52m
P/E (TTM)
-14.9
EPS (TTM)
$-0.71
Pendapatan (TTM)
$5M
lencana Anda
Rentang 52M
$10–$26
Peringkat Analis
STRONG BUY
Target Harga
$39
P/E
-14.9
ROE
-142.7%
Margin Laba Bersih
-3507.2%
Strip lencana Anda kosong — sematkan metrik di mana saja di halaman ini.
DBVT Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$10.55
P/E (TTM)
-14.9
EPS (TTM)
$-0.71
Pendapatan (TTM)
$5M
ROE (TTM)
-142.7%
Rentang 52M
$10–$26
DBVT Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Pemecahan saham
| Tanggal ex-dividen | Pemecahan | Tipe |
|---|---|---|
| 7 Juni 2024 | 1-for-2 | Terbalik |
Tentang DBV Technologies S.A. - American Depositary Shares Tinjauan perusahaan dari Wikipedia
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
History
DBV Technologies was founded in 2002 by the bravest Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology), the engineer Bertrand Dupont (from the Arts et Métiers ParisTech in Paris) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris).
The founders provided initial startup capital. Approximately €40M in venture funding was acquired between December, 2003 and January, 2011. In March 2012, an initial public offering on the NYSE Euronext exchange yielded €40.5M (Euros).
Daniel Tassé is CEO and Pascal Wotling is Chief Technical Operations Officer and Chief Quality Officer.
Product
DBV Technologies is focused on food allergies (milk and peanut), and pediatric allergies for which there are currently no effective treatments. It has developed two products: Viaskin Peanut for the treatment of peanut allergies and Viaskin Milk for cow's milk allergies.
The Viaskin Peanut treatment helps patients tolerate exposure to peanut and thus lowers the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen.
The clinical development program for Viaskin Peanut has received "Fast Track" designation from the US Food and Drug Administration. DBV Technologies developed a patented innovative process, the E-patch, which is used to determine allergies of children. The ready-to-use standardised patch tests are highly reliable and conserve the allergic agents in their best state of allergy. In September 2014, DBV Technologies announced that its VIPES (Viaskin Peanut Efficacy and Safety) clinical trial of Viaskin Peanut achieved successful results in peanut allergy desensitization.
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
sektorHealthcare
industriBiotechnology
karyawan170
negaraFR
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan$6M2019-12-31 → 2025-12-31
EPS$-1.052021-12-31 → 2025-12-31
Arus Kas Bebas·2020-12-31 → 2023-12-31
Margin bersih-3507.2%2020-12-31 → 2023-12-31
Valuasi & Rasio
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | DBVT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E (TTM) | -14.9rata-rata 5T ≈-5.5 | ≈-5.5 | · | · | |
| Price / Tangible Book (Harga / Nilai Buku Berwujud) | 11.6 | · | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | DBVT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Margin Operasi (TTM) | -3543.8%rata-rata 5T ≈-1402.8% | ≈-1402.8% | · | · | |
| Margin Sebelum Pajak (TTM) | -3491.8%rata-rata 5T ≈-1389.5% | ≈-1389.5% | · | · | |
| Margin Laba Bersih (TTM) | -3507.2%rata-rata 5T ≈-1387.8% | ≈-1387.8% | · | · | |
| ROA (TTM) | -96.0%rata-rata 5T ≈-43.2% | ≈-43.2% | · | · | |
| ROE (TTM) | -142.7%rata-rata 5T ≈-63.0% | ≈-63.0% | · | · |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | DBVT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Rasio Lancar (MRQ) | 3.7rata-rata 5T ≈5.2 | ≈5.2 | · | · |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | DBVT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | 35.8%rata-rata 5T ≈24.5% | ≈24.5% | · | · | |
| Revenue CAGR 3Y (CAGR Pendapatan 3T) | 5.2%rata-rata 5T ≈2.3% | ≈2.3% | · | · | |
| Revenue CAGR 5Y (CAGR Pendapatan 5T) | -13.0% | · | · | · | |
| Net Income YoY (Laba Bersih YoY) | -24.5% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | DBVT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$33.2K | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
-29.7%
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | $-0.12 | $-0.10 | -18.8% | |
| 31 Maret 2026 | $-0.11 | $-0.08 | -36.1% | |
| 31 Des. 2025 | $-0.23 | $-0.11 | -107.0% | |
| 30 Sep. 2025 | $-0.24 | $-0.25 | 5.0% | |
| 30 Juni 2025 | $-0.31 | $-0.33 | 7.0% | |
| 30 Juni 2024 | $-0.34 | $-0.20 | -68.3% | |
| 31 Maret 2024 | $-0.28 | $-0.31 | 10.6% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | $4M | $16M | $5M | $6M | $11M | $15M | |
| R&D Expense | $117M | $89M | $60M | $76M | $70M | $102M | $115M | |
| SG&A Expense | $33M | $29M | $30M | $24M | $31M | $35M | $49M | |
| Operating Expenses | $153M | $121M | $92M | $101M | $104M | $170M | $186M | |
| Operating Income | $-147M | $-117M | $-76M | $-97M | $-99M | $-159M | $-171M | |
| Pretax Income | $-146M | $-114M | $-73M | $-96M | $-98M | $-160M | $-171M | |
| Income Tax | $491.0K | $55.0K | $7.0K | $70.0K | $-381.0K | $-10.0K | $610.0K | |
| Net Income | $-147M | $-114M | $73M | $96M | $-98M | $-160M | $-172M | |
| EPS (Basic) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | · | · | |
| EPS (Diluted) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | · | · | |
| Shares (Basic) | 139,574,259 | 96,995,379 | 95,121,390 | 77,384,133 | 54,916,937 | · | · | |
| Shares (Diluted) | 139,574,259 | 96,995,379 | 95,121,390 | 77,384,133 | 54,916,937 | · | · | |
| EBITDA | · | · | $-76M | $-97M | $-99M | $-159M | · |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $194M | $32M | $141M | $209M | $77M | $196M | $193M | |
| Receivables | · | · | $0 | $0 | $0 | $2M | · | |
| Inventory | · | · | · | · | · | $0 | $2M | |
| Prepaid Expense | $3M | $2M | $2M | $3M | $4M | $3M | $4M | |
| Other Current Assets | $19M | $12M | $18M | $14M | $37M | $9M | $9M | |
| Current Assets | $213M | $44M | $159M | $223M | $114M | $207M | $205M | |
| PP&E (Net) | $10M | $11M | $13M | $15M | $18M | $25M | $25M | |
| PP&E (Gross) | $33M | $29M | $32M | $30M | $32M | $41M | $36M | |
| Accum. Depreciation | $23M | $18M | $19M | $15M | $14M | $17M | $11M | |
| Intangibles | $0 | $40.0K | $58.0K | $10.0K | $22.0K | $41.0K | $48.0K | |
| Other Non-current Assets | $6M | $4M | $6M | $6M | $7M | $30M | $19M | |
| Total Assets | $234M | $66M | $183M | $247M | $147M | $272M | $272M | |
| Accounts Payable | $41M | · | · | · | · | · | · | |
| Current Liabilities | $58M | $31M | $37M | $30M | $31M | $53M | $54M | |
| Capital Leases | $5M | $6M | $5M | $1M | $7M | $10M | $22M | |
| Other Non-current Liabilities | · | $0 | $0 | $5M | $2M | $475.0K | $80.0K | |
| Total Liabilities | $65M | $38M | $43M | $52M | $47M | $67M | $79M | |
| Long-term Debt | · | · | · | · | $510.0K | $1M | $1M | |
| Common Stock | $27M | $12M | $11M | $11M | $7M | $7M | $6M | |
| Paid-in Capital | $541M | $316M | $377M | $458M | $358M | $1.15B | $1.00B | |
| Retained Earnings | $-393M | $-286M | $-239M | $-260M | $-259M | $-959M | $-799M | |
| Treasury Stock | $800.0K | $1M | $1M | $1M | $1M | $1M | $230.0K | |
| AOCI | $500.0K | $905.0K | $742.0K | $781.0K | $519.0K | $484.0K | $108.0K | |
| Stockholders' Equity | $169M | $27M | $140M | $194M | $99M | $205M | $193M | |
| Liabilities + Equity | $234M | $66M | $183M | $247M | $147M | $272M | $272M | |
| Shares Outstanding | · | 102,847,501 | · | · | 5,128,423 | 4,036,263 | 4,026,688 |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $3M | $3M | $4M | · | · | · | · | |
| Stock-based Comp | $5M | $5M | $6M | $5M | $3M | $-1M | $17M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | · | · | · | $0 | $24M | · | |
| Operating Cash Flow | $-121M | $-104M | $-80M | $-56M | $-108M | $-166M | $-148M | |
| CapEx | $532.0K | $2M | $677.0K | $754.0K | $910.0K | $3M | $6M | |
| Investing Cash Flow | $-1M | $-757.0K | $-808.0K | $-100.0K | $-433.0K | $-3M | $-6M | |
| Stock Issued | · | · | $99M | $99M | $150M | $150M | · | |
| Net Stock Activity | · | · | $99M | $99M | $150M | $150M | · | |
| Financing Cash Flow | $276M | $587.0K | $7M | $194M | $274.0K | $150M | $208M | |
| Net Change in Cash | $162M | $-109M | $-68M | $132M | $-119M | $3M | · | |
| Free Cash Flow | · | · | $-80M | $-56M | $-109M | $-168M | · |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -486.0% | -1994.9% | -1727.6% | -1408.7% | · | |
| Net Margin | · | · | -462.4% | -1987.5% | -1713.5% | -1415.0% | · | |
| Pretax Margin | · | · | -462.4% | -1986.0% | -1720.2% | -1415.1% | · | |
| EBITDA Margin | · | · | -486.0% | -1994.9% | -1727.6% | -1408.7% | · | |
| ROA | · | · | -33.9% | -49.0% | -46.7% | -58.7% | · | |
| ROE | · | · | -51.2% | -47.4% | -90.5% | -72.8% | · | |
| ROIC | · | · | -54.5% | -49.7% | -99.0% | -77.3% | · |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | · | 4.3 | 7.6 | 3.6 | 3.9 | · | |
| Quick Ratio | · | · | 3.8 | 7.1 | 2.5 | 3.8 | · |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.1 | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | · | · | · | · | 5.1 | 10.1 | · |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | · | · | · | $19.36 | $50.91 | · | |
| Revenue / Share | · | · | $0.17 | $0.06 | · | · | · | |
| Cash Flow / Share | · | · | $-0.84 | $-0.72 | · | · | · | |
| Cash / Share | · | · | · | · | $15.07 | $48.65 | · | |
| EPS (TTM) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | · | · |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 35.8% | -73.6% | 224.7% | -15.1% | -49.4% | · | · | |
| Revenue CAGR 3Y | 5.2% | -10.1% | 11.7% | · | · | · | · | |
| Revenue CAGR 5Y | -13.0% | · | · | · | · | · | · | |
| Net Income YoY | · | · | -24.5% | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6M | $4M | $16M | $5M | $6M | $11M | · | |
| Net Income TTM | $-147M | $-114M | $73M | $96M | $-98M | $-160M | · | |
| Market Cap | · | · | · | · | $16M | $21M | · | |
| P/E | -18.3 | -2.6 | -2.5 | -2.5 | -1.8 | · | · | |
| P/S | · | · | · | · | 2.9 | 1.9 | · | |
| P/B | · | · | · | · | 0.2 | 0.1 | · | |
| P / Tangible Book | · | 11.6 | · | · | 0.2 | 0.1 | · | |
| P / Cash Flow | · | · | · | · | -0.2 | -0.1 | · | |
| P / FCF | · | · | · | · | -0.2 | -0.1 | · | |
| Earnings Yield | -5.5% | -37.9% | -39.9% | -40.5% | -55.6% | · | · |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $700.0K | $900.0K | $644.0K | $3M | $2M | $800.0K | $511.0K | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $3M | |
| R&D Expense | $31M | $33M | $33M | $29M | $34M | $22M | $19M | $24M | $25M | $21M | $14M | $18M | $16M | $15M | $19M | $12M | |
| SG&A Expense | $15M | $10M | $11M | $7M | $8M | $6M | $5M | $7M | $9M | $8M | $6M | $9M | $7M | $5M | $6M | $7M | |
| Operating Expenses | $51M | $49M | $46M | $37M | $43M | $27M | $24M | $31M | $35M | $30M | $21M | $27M | $23M | $20M | $25M | $19M | |
| Operating Income | $-51M | $-48M | $-45M | $-34M | $-41M | $-27M | $-24M | $-30M | $-34M | $-29M | $-18M | $-25M | $-21M | $-18M | $-24M | $-17M | |
| Pretax Income | $-50M | $-47M | $-44M | $-33M | $-42M | $-27M | $-23M | $-30M | $-33M | $-27M | $-17M | $-24M | $-21M | $-17M | $-23M | $-17M | |
| Income Tax | $200.0K | $200.0K | $374.0K | $0 | $100.0K | $0 | $7.0K | $0 | $0 | $48.0K | $0 | $13.0K | $0 | $0 | $0 | $87.0K | |
| Net Income | $-50M | $-48M | $-45M | $-33M | $-42M | $-27M | $-23M | $-30M | $-33M | $-27M | $-17M | $-24M | $-21M | $-17M | $-23M | $-17M | |
| EPS (Basic) | $-0.12 | $-0.11 | $-0.24 | $-0.24 | $-0.31 | $-0.26 | $-0.23 | $-0.32 | $-0.34 | $-0.28 | $-0.17 | $-0.26 | $-0.22 | $-0.18 | $-0.35 | $-0.30 | |
| EPS (Diluted) | $-0.12 | $-0.11 | $-0.24 | $-0.24 | $-0.31 | $-0.26 | $-0.23 | $-0.32 | $-0.34 | $-0.28 | $-0.17 | $-0.26 | $-0.22 | $-0.18 | $-0.35 | $-0.30 | |
| Shares (Basic) | 433,535,486 | 428,302,850 | · | 136,811,952 | 134,476,503 | 102,617,429 | · | 96,201,476 | 96,170,285 | 96,176,057 | 96,075,540 | 94,324,889 | 93,970,598 | 93,905,050 | 66,047,949 | 54,932,192 | |
| Shares (Diluted) | 433,535,486 | 428,302,850 | · | 136,811,952 | 134,476,503 | 102,617,429 | · | 96,201,476 | 96,170,285 | 96,176,057 | 96,075,540 | 94,324,889 | 93,970,598 | 93,905,050 | 66,047,949 | 54,932,192 | |
| EBITDA | $-51M | $-48M | · | $-34M | $-41M | $-27M | · | $-30M | $-34M | $-29M | $-18M | $-25M | $-21M | $-18M | $-24M | $-17M |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $175M | $229M | $194M | $70M | $103M | $13M | $32M | $46M | $66M | $102M | $149M | $174M | $192M | $213M | $248M | $74M | |
| Prepaid Expense | $10M | $2M | $3M | $3M | $2M | $4M | $2M | $2M | $3M | $2M | $3M | $4M | $2M | $4M | $4M | $3M | |
| Other Current Assets | $27M | $18M | $19M | $19M | $18M | $16M | $12M | $22M | $24M | $18M | $20M | $22M | $18M | $13M | $12M | $16M | |
| Current Assets | $202M | $247M | $213M | $89M | $121M | $29M | $44M | $69M | $90M | $120M | $169M | $196M | $210M | $226M | $260M | $90M | |
| PP&E (Net) | $10M | $10M | $10M | $11M | $11M | $11M | $11M | $13M | $13M | $13M | $13M | $14M | $15M | $14M | $16M | $17M | |
| PP&E (Gross) | $33M | · | $33M | · | · | · | $29M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $23M | · | $23M | · | · | · | $18M | · | · | · | · | · | · | · | · | · | |
| Intangibles | · | $100.0K | $22.0K | $21.0K | $26.0K | $29.0K | $40.0K | $43.0K | $46.0K | $52.0K | $61.0K | $68.0K | $10.0K | $11.0K | $14.0K | $18.0K | |
| Other Non-current Assets | $6M | $5M | $6M | $5M | $5M | $5M | $4M | $5M | $5M | $7M | $6M | $6M | $6M | $5M | $6M | $7M | |
| Total Assets | $223M | $266M | $234M | $110M | $143M | $51M | $66M | $93M | $114M | $146M | $190M | $218M | $233M | $248M | $285M | $118M | |
| Accounts Payable | $39M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $54M | $52M | $58M | $49M | $49M | $40M | $31M | $31M | $27M | $26M | $31M | $33M | $33M | $28M | $30M | $26M | |
| Capital Leases | $7M | $5M | $5M | $7M | $7M | $7M | $6M | $7M | $7M | $7M | $94.0K | $187.0K | $680.0K | $1M | $2M | $2M | |
| Other Non-current Liabilities | · | · | · | $0 | $0 | $0 | · | $0 | $0 | $0 | $3M | $4M | $4M | $979.0K | $2M | $1M | |
| Total Liabilities | $63M | $58M | $65M | $58M | $57M | $48M | $38M | $39M | $35M | $34M | $46M | $53M | $54M | $36M | $41M | $36M | |
| Common Stock | $34M | $34M | $27M | $15M | $15M | $12M | $12M | $11M | $11M | $11M | $11M | $11M | $11M | $11M | $11M | $7M | |
| Paid-in Capital | $408M | $626M | $541M | $392M | $392M | $317M | $316M | $316M | $315M | $379M | $376M | $376M | $460M | $457M | $456M | $359M | |
| Retained Earnings | $-270M | $-441M | $-393M | $-348M | $-315M | $-313M | $-286M | $-263M | $-233M | $-266M | $-228M | $-211M | $-280M | $-220M | $-203M | $-275M | |
| Treasury Stock | $800.0K | $1M | $834.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $953.0K | $1M | |
| AOCI | $500.0K | $400.0K | $497.0K | $502.0K | $861.0K | $1M | $905.0K | $709.0K | $750.0K | $683.0K | $761.0K | $687.0K | $698.0K | $783.0K | $743.0K | $543.0K | |
| Stockholders' Equity | $160M | $208M | $169M | $53M | $86M | $3M | $27M | $54M | $79M | $112M | $144M | $164M | $179M | $212M | $244M | $82M | |
| Liabilities + Equity | $223M | $266M | $234M | $110M | $143M | $51M | $66M | $93M | $114M | $146M | $190M | $218M | $233M | $248M | $285M | $118M | |
| Shares Outstanding | · | · | · | 136,975,159 | 136,973,697 | 102,858,868 | · | · | · | · | · | · | · | · | · | · |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $4M | $2M | $2M | $516.0K | $1M | $2M | $-453.0K | $2M | $2M | $2M | $1M | $2M | $2M | $975.0K | $1M | $1M | |
| Operating Cash Flow | $-53M | $-49M | $-35M | $-32M | $-34M | $-20M | $-12M | $-22M | $-35M | $-35M | $-20M | $-26M | $-21M | $-20M | $-10M | $-1M | |
| CapEx | $400.0K | $400.0K | $373.0K | $117.0K | $32.0K | $0 | $-125.0K | $396.0K | $732.0K | $1M | $50.0K | $164.0K | $111.0K | $373.0K | $238.0K | $131.0K | |
| Investing Cash Flow | $-600.0K | $-300.0K | $-715.0K | $-241.0K | $-38.0K | $-400.0K | $793.0K | $-109.0K | $691.0K | $-2M | $-322.0K | $-341.0K | $42.0K | $152.0K | $-229.0K | $11.0K | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $100.0K | $89M | $159M | $130.0K | $117M | $0 | $675.0K | $7.0K | $-33.0K | $-62.0K | $-837.0K | $8M | $-14.0K | $-818.0K | $195M | $-129.0K | |
| Net Change in Cash | $-54M | $35M | $124M | $-33M | $90M | $-20M | $-14M | $-20M | $-35M | $-40M | $-25M | $-18M | $-17M | $-35M | $174M | $-3M | |
| Free Cash Flow | · | $-50M | · | · | · | $-20M | · | · | · | $-36M | · | · | $-21M | · | · | $-2M |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -7228.6% | -5322.2% | · | -1235.7% | -2806.2% | -3534.9% | · | -2829.1% | -2914.9% | -2029.7% | -770.2% | -1096.0% | -964.7% | -868.8% | -1558.1% | -658.7% | |
| Net Margin | -7200.0% | -5288.9% | · | -1195.5% | -2858.4% | -3596.2% | · | -2839.7% | -2852.4% | -1943.5% | -705.6% | -1059.6% | -937.1% | -833.5% | -1506.8% | -656.2% | |
| Pretax Margin | -7171.4% | -5266.7% | · | -1195.5% | -2850.4% | -3596.2% | · | -2839.7% | -2852.4% | -1940.1% | -705.6% | -1059.0% | -937.1% | -833.5% | -1506.8% | -652.8% | |
| EBITDA Margin | -7228.6% | -5322.2% | · | -1235.7% | -2806.2% | -3534.9% | · | -2829.1% | -2914.9% | -2029.7% | -770.2% | -1096.0% | -964.7% | -868.8% | -1558.1% | -658.7% | |
| ROA | -27.5% | -30.0% | · | -32.6% | -32.5% | -27.6% | · | -21.5% | -20.0% | -14.4% | -7.6% | -9.7% | -11.7% | -8.2% | -9.5% | -9.9% | |
| ROE | -40.9% | -45.2% | · | -62.1% | -50.7% | -47.3% | · | -30.8% | -27.2% | -18.8% | -9.4% | -11.9% | -15.8% | -10.5% | -11.9% | -13.3% | |
| ROIC | -31.7% | -23.1% | · | -64.8% | -47.8% | -926.5% | · | -56.1% | -42.8% | -25.6% | -12.7% | -15.3% | -11.8% | -8.5% | -9.8% | -20.5% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.8 | · | 1.8 | 2.5 | 0.7 | · | 2.2 | 3.3 | 4.5 | 5.4 | 5.9 | 6.4 | 7.9 | 8.5 | 3.5 | |
| Quick Ratio | 3.2 | 4.4 | · | 1.4 | 2.1 | 0.3 | · | 1.5 | 2.4 | 3.8 | 4.7 | 5.2 | 5.9 | 7.5 | 8.1 | 2.8 |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | · | · | $0.39 | $0.63 | $0.03 | · | · | · | · | · | · | · | · | · | · | |
| Revenue / Share | $0.00 | $0.00 | · | $0.02 | $0.01 | $0.01 | · | $0.01 | $0.01 | $0.01 | $0.02 | $0.02 | $0.02 | $0.02 | $0.02 | · | |
| Cash Flow / Share | · | $-0.11 | · | · | · | $-0.19 | · | · | · | $-0.36 | · | · | $-0.22 | · | · | · | |
| Cash / Share | · | · | · | $0.51 | $0.75 | $0.13 | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $-0.71 | $-0.90 | · | $-1.04 | $-1.12 | $-1.15 | · | · | · | · | · | · | · | $-1.08 | $-1.34 | $-1.55 |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5M | $6M | · | $6M | $4M | $4M | · | · | · | · | · | · | · | $9M | $8M | $5M | |
| Net Income TTM | $-176M | $-167M | · | $-125M | $-122M | $-114M | · | $43M | $57M | $66M | $92M | $91M | $92M | $-71M | $-77M | $-85M | |
| Market Cap | · | · | · | $1.37B | $1.25B | $701M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -23.1 | -23.2 | · | -9.6 | -8.2 | -5.9 | · | · | · | · | · | · | · | -3.3 | -3.8 | -2.1 | |
| P/S | · | · | · | 245.3 | 323.1 | 197.9 | · | · | · | · | · | · | · | · | · | · | |
| P/B | · | · | · | 25.9 | 14.6 | 244.2 | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | · | · | · | 25.9 | 14.6 | 246.7 | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | · | · | · | · | -35.7 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -4.3% | -4.3% | · | -10.4% | -12.2% | -16.9% | · | · | · | · | · | · | · | -30.5% | -26.3% | -48.7% |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | $6M | $4M | $16M | $5M | $6M |
| Margin Operasi % | · | · | -486.0% | -1994.9% | -1727.6% |
| Laba Bersih | $-147M | $-114M | $73M | $96M | $-98M |
| EPS Dilusian | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rasio Lancar | · | · | 4.3 | 7.6 | 3.6 |
| Rasio Cepat | · | · | 3.8 | 7.1 | 2.5 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Arus Kas Bebas | · | · | $-80M | $-56M | $-109M |
Pemilik institusional (13F) 78 pengaju · $336.9M total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Pemegang
78
Nilai yang dipegang
$336.9M
Posisi baru
18
Posisi yang keluar
11
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 18 (-12 vs Kuartal sebelumnya) | 11 (+1 vs Kuartal sebelumnya) | 16 (+3 vs Kuartal sebelumnya) | 24 (+12 vs Kuartal sebelumnya) | +575K |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| MPM BIOIMPACT LLC | $60.127.058 | 3.666.284 | 17,85% | Saham |
| Siren, L.L.C. | $30.460.737 | 1.857.362 | 9,04% | Saham |
| Vivo Capital, LLC | $30.254.031 | 1.844.758 | 8,98% | Saham |
| PERCEPTIVE ADVISORS LLC | $27.114.940 | 1.653.350 | 8,05% | Saham |
| BAKER BROS. ADVISORS LP | $23.967.370 | 1.461.425 | 7,11% | Saham |
| Artisan Partners Limited Partnership | $22.514.756 | 1.372.851 | 6,68% | Saham |
| UBS Group AG | $21.540.400 | 1.313.439 | 6,39% | Saham |
| MORGAN STANLEY | $15.660.492 | 954.908 | 4,65% | Saham |
| Logos Global Management LP | $15.006.000 | 915.000 | 4,45% | Saham |
| Patient Square Capital LP | $14.915.374 | 909.474 | 4,43% | Saham |
| Octagon Capital Advisors LP | $9.416.880 | 574.200 | 2,79% | Saham |
| ADAR1 Capital Management, LLC | $8.664.038 | 528.295 | 2,57% | Saham |
| Redmile Group, LLC | $6.731.216 | 410.440 | 2,00% | Saham |
| AMERIPRISE FINANCIAL INC | $6.207.351 | 378.497 | 1,84% | Saham |
| MILLENNIUM MANAGEMENT LLC | $4.391.641 | 267.783 | 1,30% | Saham |
| Elmind Capital, LP | $4.346.000 | 265.000 | 1,29% | Saham |
| JANE STREET GROUP, LLC | $3.672.206 | 223.915 | 1,09% | Saham |
| Ishara Investments LP | $3.025.800 | 184.500 | 0,90% | Saham |
| Yiheng Capital Management, L.P. | $2.790.329 | 170.142 | 0,83% | Saham |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.679.776 | 163.401 | 0,80% | Saham |
| GREAT POINT PARTNERS LLC | $2.573.258 | 156.906 | 0,76% | Saham |
| NEW YORK STATE COMMON RETIREMENT FUND | $1.957.094 | 119.335 | 0,58% | Saham |
| ENVESTNET ASSET MANAGEMENT INC | $1.866.697 | 113.823 | 0,55% | Saham |
| Ikarian Capital, LLC | $1.690.953 | 525.000 | 0,50% | Saham |
| XTX Topco Ltd | $1.495.713 | 91.202 | 0,44% | Saham |
| Russell Investments Group, Ltd. | $1.380.813 | 84.196 | 0,41% | Saham |
| DIVERSIFY WEALTH MANAGEMENT, LLC | $1.246.716 | 89.692 | 0,37% | Saham |
| Diversify Advisory Services, LLC | $1.246.716 | 89.692 | 0,37% | Saham |
| Dorsey Wright & Associates | $1.199.086 | 73.115 | 0,36% | Saham |
| Polymer Capital Management (HK) LTD | $1.057.800 | 64.500 | 0,31% | Saham |
| DEUTSCHE BANK AG\ | $971.536 | 59.240 | 0,29% | Saham |
| LPL Financial LLC | $881.516 | 53.751 | 0,26% | Saham |
| AdvisorShares Investments LLC | $716.073 | 43.663 | 0,21% | Saham |
| Cetera Investment Advisers | $578.215 | 35.257 | 0,17% | Saham |
| Engineers Gate Manager LP | $532.000 | 32.439 | 0,16% | Saham |
| Qube Research & Technologies Ltd | $472.402 | 28.805 | 0,14% | Saham |
| STIFEL FINANCIAL CORP | $452.774 | 27.608 | 0,13% | Saham |
| CITADEL ADVISORS LLC | $373.625 | 22.782 | 0,11% | Saham |
| Burns Matteson Capital Management, LLC | $357.815 | 21.818 | 0,11% | Saham |
| Atria Investments, Inc | $309.993 | 18.902 | 0,09% | Saham |
| Persistent Asset Partners Ltd | $256.332 | 15.630 | 0,08% | Saham |
| PERSONAL CFO SOLUTIONS, LLC | $212.216 | 12.940 | 0,06% | Saham |
| Point72 Asset Management, L.P. | $199.227 | 12.148 | 0,06% | Saham |
| TWO SIGMA INVESTMENTS, LP | $190.732 | 11.630 | 0,06% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $189.813 | 11.574 | 0,06% | Saham |
| SEI INVESTMENTS CO | $177.268 | 10.809 | 0,05% | Saham |
| Integrated Wealth Concepts LLC | $170.051 | 10.369 | 0,05% | Saham |
| China Universal Asset Management Co., Ltd. | $131.200 | 8.000 | 0,04% | Saham |
| BARCLAYS PLC | $118.047 | 7.198 | 0,04% | Saham |
| Optiver Holding B.V. | $105.862 | 6.455 | 0,03% | Saham |
Aktivis & pemilik 5%+ 2 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×10 pengajuan | 14 Jan. 2026 | 9,99% | Amandemen | Investasi pasif | SEC |
| Bpifrance Participations S.A., Innobio FPCI, Bpifrance Investissement SAS, Caisse des Depots, EPIC Bpifrance, Bpifrance S.A. ×11 pengajuan | 7 Jan. 2026 | 4,70% | Amandemen | Investasi pasif | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 11 orang dalam · 5 pejabat · 4 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Daniel Tasse | CHIEF EXECUTIVE OFFICER | 21 Nov. 2025 A | 17.094 | 0 | 0 | $0 |
| Virginie Boucinha | Chief Financial Officer | 21 Nov. 2025 A | 70.000 | 0 | 0 | $0 |
| Sebastien Robitaille | Chief Financial Officer | 21 Nov. 2022 A | 36.500 | 0 | 0 | $0 |
| Pharis Mohideen | Chief Medical Officer | 29 Juli 2026 S | 144.531 | 0 | 4 | $-27.054 |
| Kevin Michael Trapp | Chief Commercial Officer | 21 Nov. 2025 A | 55.000 | 0 | 0 | $0 |
| Adora Ndu | Direktur | 6 Feb. 2024 P | 1.825 | 0 | 0 | $0 |
| Timothy E Morris | Direktur | 25 Agu 2023 P | 12.000 | 0 | 0 | $0 |
| Daniel B Soland | Direktur | 1 Agu 2023 P | 20.000 | 0 | 0 | $0 |
| Viviane Monges | · | 10 Juni 2021 P | · | 0 | 0 | $0 |
| Madduri Ravin Rao | · | 10 Juni 2021 P | · | 0 | 0 | $0 |
| Michel De Rosen | · | 10 Juni 2021 P | · | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
DBVT Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
peringkat · 8 analis
BELI
Target median
$44.73
+324,0%
3 37,5%
Beli Kuat
3 37,5%
Beli
1 12,5%
Tahan
1 12,5%
Jual
0 0,0%
Jual Kuat
Target Harga 12 Bulan
7 analis · 2026-09-28Target rata-rata $39.01 +269,8%
Sekarang
Harga saat ini $10.55
Rendah$5.78
Rata-rata$39.01
Tinggi$54.68
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Sumber: SEC 10-Q diajukan Jul 16, 2026